AnHeart Therapeutics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
AnHeart Therapeutics Inc. - overview
Established
2018
Location
New York, NY, US
Primary Industry
Biotechnology
About
Founded in 2018, and based in New York, US, AnHeart Therapeutics Inc. is a multinational clinical-stage biopharmaceutical business that creates treatments for cancer patients. The company was founded by its CEO, Junyuan Jerry Wang, and President Bing Yan. In April 2024, Nuvation Bio, Inc.
acquired AnHeart Therapeutics (Hangzhou) Co. , Ltd. from Decheng Capital, China Merchants Capital, Cenova Ventures, and Innovent Biologics, Inc. Following the acquisition, AnHeart Therapeutics shareholders own 33%, and the stockholders of Nuvation Bio own 67% of Nuvation Bio on a fully diluted basis.
AnHeart Therapeutics develops, creates, and commercializes biotechnology-based novel oncology medicines and treatments for patients suffering from cancer. As of 2024, the company’s product pipeline includes clinical-stage therapeutic cancer treatments such as taletrectinib (a ROS1 inhibitor) and safusidenib (a mIDH1 inhibitor). The treatments significantly enhance patient health by focusing on and attacking vital pathways in cancer cells.
Current Investors
Decheng Capital, China Merchants Capital, Cenova Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.anhearttherapeutics.com/
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.